Dr Constantine Tam is the Director of Hematology at the St Vincen’t Hospital (Melbourne, Australia), as well as the Disease Group Lead for CLL and Low Grade Lymphoma at the Victorian Comprehensive Cancer Center.
Dr Tam graduated M.B.B.S.(Hons) in 1998, completed hematology training in Melbourne and at the MD Anderson Cancer Center, and was awarded Doctor of Medicine by thesis in 2009. He is an internationally recognized expert in targeted therapies for B-cell malignancies, and leads multiple clinical trials for the novel BTK inhibitor BGB-3111, as well as the first clinical trial in the world to combine ibrutinib and venetoclax.
Dr Tam has published 114 peer-reviewed articles, 5 book chapters, and 114 conference presentations, and receives research funding from the Victorian Cancer Agency, NHRMC, Leukemia and Lymphoma Society, AICR, St Vincent’s Research Endowment Fund, CLL Global Research Foundation, Viertel Charitable Foundation, Equity Trustees and the CASS Foundation. In 2013, Dr Tam was awarded the Herman Clinical Fellowship for Translational Cancer Research by the University of Melbourne.